Organic Active Ingredients TRIZ Cases

Acidic ion-exchange resins remove gelling cations from kappa carrageenan, lowering melting points without depolymerizing the polymer chains.

Modulable cyclometalated iridium(III) complexes resolve low solubility and poor selectivity in prostate and bladder cancer treatment.

Optimizing pH to 3.0-5.0 with chlorobutanol reduces impurities in fluorescein and benoxinate ophthalmic compositions.

EPA-based pharmaceutical composition reduces remnant-like particle cholesterol and triglycerides, addressing inadequate cardiovascular treatment efficacy.

Controlled mixing and pressing parameters ensure homogeneous marker distribution, resolving industrial scale production variability.

Antisense oligonucleotides targeting AGT mRNA reduce protein levels to overcome limited RAS inhibition in resistant hypertension.

Syk inhibitors reduce reactive oxygen species damage during reperfusion, preventing additional tissue injury.

Modifying dihydroindolone structures enhances migration inhibition, addressing insufficient metastasis control in conventional anticancer therapies.

N-(substituted-phenyl)-sulfonamide compounds inhibit PERK kinase to treat proliferative disorders where existing therapies lack sufficient therapeutic efficacy.

A retinoid-lipid drug carrier delivers siRNA to stellate cells using fat-soluble vitamin compounds and cationic lipids.

Novel pyrroloquinolinyl-pyrrolidine-2,5-dione compounds inhibit c-Met receptor tyrosine kinase activity.

Formula I pyridine compounds inhibit viral replication by targeting specific sites, reducing off-target effects and mortality.

Segmented antisense libraries and optimized parameters enable consistent exon skipping, resolving variability in splicing site targeting.

Dynamic pH-responsive lipids enable endosomal escape of siRNA, resolving the trade-off between nanoparticle stability and intracellular release efficiency.

Novel salt forms of a quinuclidinyl carbamate compound act as potent glucosylceramide synthase inhibitors.

Deuterated compounds reduce 18F fluoride accumulation in the skull to improve tau protein imaging accuracy.

Formula I compounds inhibit YTHDF2/3 proteins to increase survival time in IPF and NASH.

Niclosamide derivatives block TMEM16A channels, reducing excessive mucus production and inflammation in cystic fibrosis patients.

Bioresorbable scaffolds release angiogenic factors to promote blood vessel growth and enhance vascular health.

PQQ esters replace degrading vitamin E to prevent pro-oxidative products while promoting cellular energy production.

Fluorinated hexose intermediates enable segmented gemcitabine production, reducing synthetic effort and process complexity.

Acroceras macrum gold nanoparticles stimulate osteoblast differentiation and proliferation to support bone regeneration therapies.

Targeted p38 kinase inhibitor therapy overcomes corticosteroid resistance in low-eosinophil chronic obstructive pulmonary disease patients.

Spray drying creates stable active-rich domains dispersed in a matrix, preventing agglomeration and improving bioavailability.

A topical pharmaceutical composition merges an antimitotic pyrimidine derivative with a furanylmethylene glucitol to treat psoriasis.

Cyclodextrin inclusion complexes increase meloxicam solubility, overcoming poor aqueous dissolution to accelerate pain relief in migraine attacks.

Formula I compounds inhibit the NS5A protein function to overcome side effects and resistance issues associated with standard interferon therapies.

Ion-pair bonding between ulipristal acetate and anionic polymers delays gastrointestinal absorption without increasing disintegration time.

Combining tyrosine-arginine dipeptide with niacinamide creates a synergistic substance P antagonist composition.

Benzene fused heterocyclic derivatives inhibit autotaxin to address the lack of effective inhibitors for cancer and fibrosis treatments.

Nitrogen gas drying reduces water activity below 0.20 in BIBW 2992 formulations, preventing hydrolytic degradation during manufacturing.

A self-emulsifying drug delivery formulation solubilizes the lipophilic NRC-AN-019 compound in gastric fluids to improve absorption rates.

Pharmacological modulation of BMI1 or MEN1-KMT2A induces fetal hemoglobin, bypassing complex bone marrow transplants and low-efficiency hydroxyurea treatments.

A bilayer EVA vaginal ring delivers progesterone through a drug-free film layer enclosing a medicated core.

Inductive coupling of a wireless electrode to the splanchnic nerves increases energy expenditure and reduces food intake without surgical side effects.

Selected reaction monitoring mass spectrometry quantitates specific Her2 peptide fragments directly from tumor tissue samples.

Ginseng berry polysaccharides inhibit neuraminidase activity to block influenza virus infection mechanisms.

Compounds targeting the NMDA receptor glycine site resolve the trade-off between fast onset and psychometric side effects found in ketamine.

Formula I compounds inhibit MAP4K1 kinase activity via structural modifications, resolving selectivity versus efficacy trade-offs in cancer treatment.

Co-formulating NMDA and mu-opioid receptor modulators reduces abuse potential of NMDA modulators by occupying at least 10% of mu-opioid receptors in vivo.

Veneroida bivalve glycogen suppresses blood acetaldehyde accumulation by mediating complete conversion to acetic acid.

Butylpyridinium derivatives activate satellite cells to differentiate myoblasts, addressing muscle weakness without hormonal side effects.

Amido spirocyclic amide and sulfonamide derivatives inhibit NAMPT to induce tumor cell apoptosis while maintaining cellular energy metabolism.

Dynamic aminosterol dosing calibrates individual patient response to improve treatment reliability without complex administration procedures.

RNA interference targets ghrelin mRNA to lower hormone levels, addressing obesity treatment side effects.

Disodium salt form of zoledronic acid improves oral bioavailability for treating bone-related conditions.